Luana Marano
Avellino, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
Journal: American journal of hematology
Published: February 05, 2026
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.
Journal: Annals of hematology
Published: August 01, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Journal: Annals of hematology
Published: April 18, 2025
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Journal: The Lancet. Haematology
Published: January 13, 2025
Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten.
Journal: American journal of hematology
Published: August 15, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
Journal: European journal of haematology
Published: July 23, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Journal: The New England journal of medicine
Published: March 13, 2024
Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin in Patients with Hematological Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical and Matched Unrelated Donors: A Real-Life Experience.
Journal: Hematology reports
Published: December 24, 2023
The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
Journal: British journal of haematology
Published: October 31, 2022
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Journal: Immunological reviews
Published: September 16, 2022
Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future.
Journal: The Lancet. Haematology
Published: July 11, 2022
Last Updated: 09/26/2026